Investing.com - Arcus Biosciences (NYSE: RCUS) reported third quarter EPS of $-1.00, $0.02 better than the analyst estimate of $-1.02. Revenue for the quarter came in at $48M versus the consensus estimate of $38.95M.
Arcus Biosciences's stock price closed at $15.73. It is up 0.77% in the last 3 months and down -4.38% in the last 12 months.
Arcus Biosciences saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Arcus Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Arcus Biosciences's Financial Health score is "good performance".
Check out Arcus Biosciences's recent earnings performance, and Arcus Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar